Dendritic cell Immunotherapy in HIV

Dr. Miller’s research focuses on the study of myeloid dendritic cell dysregulation during HIV-1 infection and dendritic cell-based immunotherapeutic strategies for HIV–infected individuals. Dr. Miller is involved with pre-clinical investigations of multiple recombinant viral and bacterial vectors for DC-targeting immunotherapies.  Furthermore, she evaluates the clinical use of adjuvants for HIV immunotherapies, including toll-like receptor agonists, to enhance innate immune responses during chronic infection and disrupt HIV latency.

Elizabeth Miller, MD. Assistant Professor

Contact Us

1470 Madison Avenue Room 201
New York, NY 10029 | USA
212-824-8427